ATE524472T1 - Als plk1-inhibitoren geeignete substituierte pyrimidodiazepine - Google Patents

Als plk1-inhibitoren geeignete substituierte pyrimidodiazepine

Info

Publication number
ATE524472T1
ATE524472T1 AT08717594T AT08717594T ATE524472T1 AT E524472 T1 ATE524472 T1 AT E524472T1 AT 08717594 T AT08717594 T AT 08717594T AT 08717594 T AT08717594 T AT 08717594T AT E524472 T1 ATE524472 T1 AT E524472T1
Authority
AT
Austria
Prior art keywords
substituted
pyrimidodiazepines
plk1 inhibitors
plk1
inhibitors
Prior art date
Application number
AT08717594T
Other languages
German (de)
English (en)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE524472(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE524472T1 publication Critical patent/ATE524472T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT08717594T 2007-03-22 2008-03-11 Als plk1-inhibitoren geeignete substituierte pyrimidodiazepine ATE524472T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
ATE524472T1 true ATE524472T1 (de) 2011-09-15

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08717594T ATE524472T1 (de) 2007-03-22 2008-03-11 Als plk1-inhibitoren geeignete substituierte pyrimidodiazepine

Country Status (23)

Country Link
US (1) US7517873B2 (enExample)
EP (1) EP2139892B1 (enExample)
JP (1) JP5087640B2 (enExample)
KR (1) KR101157848B1 (enExample)
CN (2) CN101636399B (enExample)
AR (1) AR065794A1 (enExample)
AT (1) ATE524472T1 (enExample)
AU (1) AU2008228303B2 (enExample)
BR (1) BRPI0809088A2 (enExample)
CA (1) CA2680757A1 (enExample)
CL (1) CL2008000785A1 (enExample)
CY (1) CY1112102T1 (enExample)
DK (1) DK2139892T3 (enExample)
ES (1) ES2371832T3 (enExample)
HR (1) HRP20110807T1 (enExample)
IL (1) IL200617A (enExample)
MX (1) MX2009010034A (enExample)
PE (1) PE20120495A1 (enExample)
PL (1) PL2139892T3 (enExample)
PT (1) PT2139892E (enExample)
SI (1) SI2139892T1 (enExample)
TW (1) TWI363629B (enExample)
WO (1) WO2008113711A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001677A (es) * 2007-08-15 2010-03-11 Vertex Pharma Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
PL2205603T3 (pl) * 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2303889A1 (en) * 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
CA2748181C (en) 2009-01-06 2019-07-16 Nathanael S. Gray Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
TWI483941B (zh) 2009-06-17 2015-05-11 Vertex Pharma 流感病毒複製之抑制劑
SI2477987T1 (en) 2009-09-14 2018-03-30 Gilead Sciences, Inc. MODULATORS TO TOLL OF LIKE RECEPTORS
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
SMT201900450T1 (it) 2013-11-13 2019-09-09 Vertex Pharma Inibitori della replicazione di virus dell’influenza
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
ES2930667T3 (es) 2014-07-11 2022-12-21 Gilead Sciences Inc Moduladores de receptores de tipo Toll para el tratamiento de VIH
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
TWI780423B (zh) 2014-09-16 2022-10-11 美商基利科學股份有限公司 類鐸受體調節劑的製備方法
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
AU2016319785C1 (en) 2015-09-11 2021-04-01 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
KR20180081809A (ko) 2015-11-25 2018-07-17 다나-파버 캔서 인스티튜트 인크. 2가 브로모도메인 억제제 및 그의 용도
EP3440084B1 (en) * 2016-04-07 2022-12-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
WO2021061894A1 (en) * 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
JP7440940B2 (ja) * 2020-03-27 2024-02-29 オップテラ インコーポレイテッド Ｐｌｋ１の選択的分解誘導化合物
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
IL310678A (en) * 2021-08-10 2024-04-01 Uppthera Inc A new compound that induces PLK1 degradation
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE380814T1 (de) * 1999-09-17 2007-12-15 Abbott Gmbh & Co Kg Kinaseinhibitoren als arzneimittel
NZ531928A (en) * 2001-09-04 2005-10-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AR065794A1 (es) 2009-07-01
CL2008000785A1 (es) 2009-03-27
US20080234255A1 (en) 2008-09-25
PT2139892E (pt) 2011-11-21
PE20120495A1 (es) 2012-05-12
US7517873B2 (en) 2009-04-14
PL2139892T3 (pl) 2012-03-30
SI2139892T1 (sl) 2011-12-30
CN101636399B (zh) 2012-04-18
EP2139892B1 (en) 2011-09-14
CY1112102T1 (el) 2015-11-04
HK1139936A1 (en) 2010-09-30
CN102746175B (zh) 2014-01-15
EP2139892A1 (en) 2010-01-06
JP2010521514A (ja) 2010-06-24
WO2008113711A1 (en) 2008-09-25
BRPI0809088A2 (pt) 2014-09-09
TWI363629B (en) 2012-05-11
CN102746175A (zh) 2012-10-24
JP5087640B2 (ja) 2012-12-05
KR20090119913A (ko) 2009-11-20
DK2139892T3 (da) 2011-12-12
TW200843781A (en) 2008-11-16
IL200617A (en) 2014-02-27
CA2680757A1 (en) 2008-09-25
ES2371832T3 (es) 2012-01-10
CN101636399A (zh) 2010-01-27
KR101157848B1 (ko) 2012-07-11
IL200617A0 (en) 2010-05-17
AU2008228303A1 (en) 2008-09-25
HRP20110807T1 (hr) 2011-12-31
MX2009010034A (es) 2009-10-12
AU2008228303B2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
ATE524472T1 (de) Als plk1-inhibitoren geeignete substituierte pyrimidodiazepine
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
CY2017016I1 (el) Αναστολεις πρωτεασωματος
ATE522535T1 (de) Pyrrolotriazin-kinasehemmer
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
BRPI0813500A2 (pt) Compostos antivirais
UY3776Q (es) Reloj pulsera
DK2242759T3 (da) Forbindelser
BRPI0821086A2 (pt) Compostos inseticidas
BRPI0811264A2 (pt) Compostos
BRPI0918564A2 (pt) inibidores
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2297162T3 (da) Forbindelser
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0809996A2 (pt) Compostos
BRPI0916432A2 (pt) compostos
BRPI0815181A2 (pt) Compostos
UY3860Q (es) Reloj
DE112008002921A5 (de) Bohrfutter
DK2206698T3 (da) Ethynylindolforbindelser
EP2177529A4 (en) NEW SECRETASE HEMMER
BRPI0814613A2 (pt) Compostos
PL3825306T3 (pl) Związki morfinanu

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2139892

Country of ref document: EP